REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy 18 patients have been dosed at leading retinal surgery centers in the United States Anticipate reporting topline data in late 2018 ROCKVILLE, Md., Feb. 08, 2018 (GLOBE …